TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced the start of a post-approval clinical study with Ceplene® (histamine dihydrochloride) following Ethics Committee and Competent Authority approvals in Sweden, Belgium, and France. This study will fulfill the post approval commitments requested by the European Medicines Evaluation Agency (EMEA) in granting marketing authorization. Ceplene® is indicated for remission maintenance in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene®is to be administered in conjunction with low-dose interleukin-2 (IL-2).
